About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72834 record(s)
Req # A-2021-001487
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: 000936085, E2B_03628058, E2B_03863854, E2B_03642326, E2B_03853345, E2B_03656279, E2B_04055896, E2B_03644690, E2B_03671794, E2B_03850124, E2B_03839607, E2B_03673968, E2B_03821748.Organization: Health Canada
March 2024
Req # A-2021-001520
Adverse Drug Reactions (ADRs). Report numbers: E2B_04568612, E2B_04527571, E2B_04559073.Organization: Health Canada
March 2024
Req # A-2021-001750
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_04446085, E2B_04399700.Organization: Health Canada
March 2024
Req # A-2021-001870
Adverse Drug Reactions (ADRs) for PNEUMOVAX 23. Report numbers: E2B_02557027, E2B_02575489, E2B_02576470. ADRs for POSANOL. Report numbers: 000726041, E2B_02412072, E2B_02435616, E2B_02437067, E2B_02248368, 000714601, E2B_02060910.Organization: Health Canada
March 2024
Req # A-2021-002091
Adverse Drug Reactions (ADRs). Report numbers: 956643, 956818, 957468, 959483, 960079, 953979, 954435, 955955, 956401, 956812, 958170, 960083, 961290, E2B_04376646, E2B_04369180, E2B_04649779, E2B_04651440, E2B_04668243, E2B_04669463, E2B_04678452.Organization: Health Canada
March 2024
Req # A-2022-000062
Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: 000979424, E2B_04993704, E2B_05010527, E2B_04988451, E2B_04988450, E2B_05049012, E2B_05077952, E2B_05027959, E2B_05082845, 000979676.Organization: Health Canada
March 2024
Req # A-2022-000381
Adverse Drug Reactions (ADRs). Report numbers: E2B_05285073, E2B_05266145, E2B_05222090, E2B_05298555, E2B_05305973, E2B_05290341, E2B_05254658, E2B_05297980, E2B_05226096, E2B_03841771.Organization: Health Canada
March 2024
Req # A-2022-000456
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-105622-54.Organization: Health Canada
March 2024
Req # A-2022-000570
Adverse Drug Reactions (ADRs). Report numbers: E2B_01232092, E2B_04569236, E2B_04894400, E2B_04456749, E2B_03190583, 000984733, E2B_04993720, E2B_04926588, E2B_05014602, 000978865.Organization: Health Canada
March 2024
Req # A-2022-000571
Adverse Drug Reactions (ADRs). Report numbers: E2B_05034900, E2B_04906981, E2B_04922179, E2B_04933182, 000974320, E2B_04877486, E2B_03433916, 000964009, 000973926, 000976615.Organization: Health Canada
March 2024